Uvodnik by Levanat, Sonja & Vrbanec, Damir
PERIODICUM BIOLOGORUM UDC 57:61 
VOL. 116, No 4, 335–336, 2014 CODEN PDBIAD 
 ISSN 0031-5362
This issue of PB is entirely dedicated to cancer. Decades ago, cancer was clonal disease  initiated from a single cell, but since then vast 
heterogeneity within and across tumor types has been discovered. We 
now know that any single tumor sample is unique and may contain more 
than a hundred different mutations.
Huge body of factual knowledge has been accumulating through 
basic research in fast advancing fields of genetics, cellular biology and 
immunology, accompanied by a virtual maze of working hypotheses 
and tentative explanations of underlying mechanisms. On a higher con-
ceptual level, quest for organizing principles that may provide logical 
framework for understanding the remarkable diversity of neoplastic 
diseases has been attempting to match the inflow of research data. 
Among such frameworks, perhaps the widest recognition has been 
achieved by the evolving proposition of cancer hallmarks, defined as the 
abilities of cancer to sustain proliferative signaling, evade growth sup-
pressors, resist cell death, enable replicative immortality, induce angio-
genesis, activate invasion and metastasis etc.
It remains to be seen whether and how this diverse and proliferative 
research may be aided by the high level conceptual frameworks in the 
ambitious task of understanding and defeating cancer. In the meantime, 
however, quite a few among numerous poorly correlated facets of ex-
perimental investigation have already made notable progress towards 
clinical applications.
Rapidly growing numbers of potential therapeutic targets are identi-
fied almost daily, involving various signaling pathways or separate genes 
and proteins, within tumors or in their microenvironment. While most 
of them are still tentative, yet to be investigated on models, some have 
made it to clinical trials and few to actual cancer therapy.
Until more complete conceptual understanding of malignant pro-
cesses, which may shed more light on important unanswered questions 
related to immune response, drug resistance and other cancer features 
interfering with therapy, oncology will continue to explore potential 
therapeutic targets revealed through versatile experimental research of 
particular cancer properties.
This issue of PB addresses very different aspects of the vast „sum of 
knowledge“ constituting present-day oncology, reflecting versatile inter-
ests of the contributors as well as the notorious fact that cancer is not 
just one disease but comprises variety of integrated damages in whole 
organism. Various aspects of cancer-related research, presented in this 
issue through original scientific articles and reviews, are briefly depicted 
below.
Some contributions address closely related themes of cancer research, 
but occasionally from a very different perspective. For example, one of 
the contributions integrates the classic understandings of the mechanis-
tic role of obesity in cancer, implying obesity-related carcinogenic pro-
cesses, whereas another one suggests a beneficial role of brown fat to 
humans.
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On the other hand, the study of cancer-related hy-
poxia is an example of a stand-alone theme, although 
hypo xic regions are common characteristic of majority of 
solid neoplasms, resulting from discordance between high 
metabolic needs of rapid growing malignant tissues and 
oxygen supply through structurally and functionally im-
paired microvasculature. Activation of hypoxia signaling 
pathways stimulates neoangiogenesis, induces transcrip-
tion of tumor promoting genes leading to increased tumor 
cell proliferation and metastatic potential.
Two contributions address related aspects of cancer 
immunology. Tumor microenvironment, not only tumor 
cells and not only stroma but also other cells, such as 
infiltrated lymphocytes, contribute to malignancy. 
Chronic inflammation increases risk of cancer, and in-
flammatory microenvironment, including action of dif-
ferent cells like macrophages and activated T lympho-
cytes, is involved in the immune response against tumor, 
and in respect to tumor type could have different out-
comes. Recent positive results with the relatively novel 
immunotherapeutic anti-cancer strategies such as adop-
tive T cell transfer, engineered T cells with chimeric an-
tigen receptors, therapeutic anti-cancer vaccine and 
checkpoint blockade inhibitors, do indicate that patient’s 
immune system can be effectively used against autologous 
tumor cells. Interactions between the immune system and 
the malignancy are complex but the results are promising 
and are undergoing active clinical testing. 
Finally, most contributions in this issue are concerned 
with proliferative signaling, some addressing the role of 
signaling pathways on a rather general level, whereas oth-
ers are limited to a particular tumor context. 
Misregulation of molecular signaling pathways that 
control fundamental cellular processes such as cell growth, 
cell division and cell death has been directly associated 
with a variety of cancer diseases. Aberrant activation of 
particular pathway or pathways, involving receptor tyro-
sine kinases, frequently occurs during cancer initiation 
and progression, and these tumorigenic cascades may co-
operate through multiple signaling cross-talks in the ma-
lignant transformation of cells, treatment resistance and 
disease relapse. For example, in thyroid cancer genetics, 
alterations exert oncogenic potential through Mitogen-
activated protein kinase (MAP kinase) pathway where 
BRAF mutation is the most common genetic alteration.
On the other hand, targets against VEGF, VEGFR 
and mTOR continue to play a crucial role in the manage-
ment of metastatic renal cell cancer, although complete 
response is extremely rare, probably because resistance in 
tumor cells develops frequently and adverse effects of 
therapy are not unusual finding.
Importance of steroid receptors in some tumors is well 
known. In case of prostate carcinoma androgen receptors 
are a major signaling pathway for survival. But activation 
of enzyme machinery or de novo production of androgen 
within the cells is a two way road. For breast cancer both 
the estrogen and progesterone receptor status are markers 
for prognosis as well as a guide for adjuvant therapy.
In spite of a broad variety of cancer-related themes in 
this PB issue, the contributions generally tend to incor-
porate one common consideration – therapeutic potential 
of the cancer research described. Clinical relevance of 
basic research has become almost mandatory ingredient 
in recent research strategies.
Although we are still quite far from truly personalized 
and efficient therapies for various cancers, this accelerat-
ing quest for potential therapeutic targets across the entire 
basic research domain has greatly expanded creative in-
teractions with clinical practice.
